Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.
Immunotherapy approaches with antigen-specific cytotoxic T lymphocytes (CTLs) have proved safe and effective prophylaxis and treatment of Epstein-Barr virus (EBV)-associated lymphomas arising after bone marrow transplantation. EBV is also associated with other malignancies including about 40% of cases of Hodgkin's disease making this tumor another potential target for EBV-targeted immunotherapy. While studies with autologous EBV-specific CTLs have shown antiviral activity and immune effects, the clinical responses have been less impressive than those observed in post-transplant lymphomas. There are several possible reasons why the malignant cells in EBV-positive Hodgkin's disease may be less susceptible to immunotherapy approaches, including the fact that they express a more restricted array of EBV-encoded antigens and possess many immune evasion strategies. A number of approaches to overcome these tumor evasion strategies including targeting CTLs to the expressed antigens and genetic modification of CTLs are being evaluated.
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas 77030, USA.
M Helen
MH
Huls
Cliona M
CM
Rooney
Helen E
HE
Heslop
D019264:Adoptive Transfer; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000276:immunology; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D006801:Humans; D013601:T-Lymphocytes